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Duchenne muscular dystrophy (DMD) is a chronic,
complex, genetic childhood disease affecting boys, where
sufferers typically die in their 20s. DMD is caused by
mutations in the dystrophin gene and trials are currently
underway with exon skipping, a therapy which works by
patching the mutation thereby allowing production of a
functional gene. The dystrophin gene contains 79 exons
and mutations can be found in one or more exons.
Treatment must be targeted to the specific exon which
is at fault and each one therefore requires a different
exon skipping chemistry. The success of trials with exon
skipping will present patients and physicians with the
possibility of a personalised medicine and with that, a
number of ethical issues. Firstly, equity and harm by
omission. Exons for the most common mutations will
be tested first and researchers assert that conforming to
the existing regulatory pathway for every exon, it will
not be cost effective. This raises the real possibility of
those children with rarer exons being denied a poten-
tially lifesaving treatment. Secondly, if therapies are
developed for the rarer mutations, risk and uncertainty
become more difficult to assess. In some cases a boy
may be his own control in a RCT and the boundaries
between experiment and therapy become blurred.
Thirdly, justice and minimum entitlement: given that
minimum entitlement in this case is likely to be very
expensive (the comparable myozome therapy costs
$300,000 per person, per year), the distribution of lim-
ited health resources throughout a population is once
again under scrutiny. This paper aims to anticipate
these ethical issues with a view to helping researchers,
clinicians, regulators and patient organisations to find
ways to ensure that the development of these life-saving
therapies progresses.
Published: 19 October 2010
doi:10.1186/1750-1172-5-S1-P8
Cite this article as: McCormack: Cell therapies for Duchenne muscular
dystrophy: some ethical issues for personalised medicines. Orphanet
Journal of Rare Diseases 2010 5(Suppl 1):P8.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Correspondence: mccormack@ncl.ac.uk
Research Associate, Newcastle University, Policy, Ethics & Life Sciences,
Citygate, Newcastle upon Tyne, NE1 4JH, UK
McCormack Orphanet Journal of Rare Diseases 2010, 5(Suppl 1):P8
http://www.ojrd.com/content/5/S1/P8
© 2010 McCormack; licensee BioMed Central Ltd.
